Synopsis: Small-cap shares jumped 20% after Q4 results, with revenue rising 16.5% YoY from ₹603 crore to ₹703 crore, along with their revenue growth guidance and top brokerage views on results and operations.
The shares of the Small-cap, specialised in providing accurate, high-quality pathology, microbiology, molecular diagnostics, and radiology services, along with preventive health checkups, home sample collection, and corporate health services, are in focus as they have surged 20 percent following their Q4 results, guidance, and brokerage views.
With a market capitalisation of Rs. 26,217.33 crore in the day’s trade, the shares of Dr. Lal PathLabs Ltd hit a 20 percent upper circuit, making a high of Rs. 1,641.70, compared to the previous close of Rs. 1,368.10.
What Happened
Dr. Lal PathLabs Ltd, engaged in providing accurate, high-quality pathology, microbiology, molecular diagnostics, and radiology services, along with preventive health checkups, home sample collection, and corporate health services, is in the spotlight following their Q4 results as follows:
Its Revenue from operations rose by 16.5 percent YoY from Rs. 603 Crores in Q4FY25 to Rs. 703 Crores in Q4FY26, and it rose by 6.5 percent QoQ from Rs. 660 Crores in Q3FY26 to Rs. 703 Crores in Q4FY26.
Its Net Profit YoY declined by 15 percent from Rs. 156 Crores in Q4FY25 to Rs. 132 Crores in Q4FY26, and on a QoQ basis, it increased by 44.4 percent from Rs. 91.4 Crores in Q3FY26 to Rs. 132 Crores in Q4FY26.
The earnings per share (EPS) for the quarterly period stood at Rs. 7.84, compared to Rs. 9.26 in the previous year’s quarter. The Company has recommended a final dividend of Rs. 4/- per equity share (40% on the face value of Rs. 10/- each) for the financial year ended March 31, 2026, and set the record date on June 26, 2026.
Guidance
Dr Lal PathLabs expects revenue growth of 13–15% in the financial year ending March 2027 (FY27), driven mainly by higher patient and sample volumes, according to CEO Shankha Banerjee. The company has no immediate plans to raise prices but continues to monitor cost pressures and external factors.
In FY26, the lab reported a 5.2% increase in volumes and overall revenue growth of around 12.2%, supported by both volume gains and improvements in product and geographic mix. Banerjee expects this mix benefit to continue, helping bridge the gap between modest volume growth and overall revenue targets.
Brokerage Views
Morgan Stanley on Dr Lal PathLabs
Morgan Stanley maintains an Overweight rating on Dr Lal PathLabs with a target price of Rs 1,819, highlighting strong operational momentum. The lab reported Q4 revenue growth of 16.6% YoY, its highest in 15 quarters, driven by robust demand across diagnostics services. This performance underscores the company’s ability to consistently deliver strong top-line growth.
Looking ahead, Dr Lal PathLabs has guided FY27 revenue growth of 13–15%, signaling sustained expansion in the diagnostic sector. If the company continues this trajectory, investor confidence could drive a re-rating, making the stock an attractive proposition for medium- to long-term investors seeking exposure to healthcare diagnostics.
Citi on Dr Lal PathLabs
Citi has maintained a Buy rating on Dr Lal PathLabs with a target price of Rs 1,700, citing strong Q4 growth and an improved business outlook. The company’s robust performance reflects healthy demand across its diagnostic services and operational efficiency.
The lab has raised its revenue guidance to 13–15% for FY27, reinforcing confidence in its growth trajectory. Citi remains positive on the company’s medium- to long-term prospects, viewing sustained expansion as a key driver for shareholder value.
Nomura on Dr Lal PathLabs
Nomura has maintained a Buy rating on Dr Lal PathLabs with a target price of Rs 1,860, noting that 4QFY26 growth is accelerating. While revenue for the quarter came in ahead of estimates, EBITDA remained in line, reflecting operational stability amid strong top-line momentum.
The brokerage highlights that volume-driven growth is expected to support higher valuations, especially as current stock levels are near seven-year lows, presenting an attractive entry point for investors. Sustained increase in diagnostic volumes is seen as a key catalyst for re-rating the stock.
Additionally, Nomura emphasizes that DLPL’s valuation multiple is underpinned by a robust balance sheet, enabling the company to pursue strategic acquisitions. Combined with strong volume growth, this positions Dr Lal PathLabs well for long-term value creation and expansion in the diagnostics space.
Goldman Sachs on Dr Lal PathLabs
Goldman Sachs has issued a Sell rating on Dr Lal PathLabs with a target price of Rs 1,300, even as 4QFY26 sales and EBITDA grew 16.6% and 10.5% YoY, outperforming their estimates. The growth was largely driven by strong volume momentum (patients +8.2%, samples +12.9% YoY) and an improved test and geographic mix, with revenue per patient rising 7.8% YoY.
EBITDA margin for the quarter was 26.6%, slightly lower than 28.1% in 4QFY25 but in line with GS estimates. Management emphasized a calibrated pricing approach and ongoing reinvestment to support long-term growth, signaling a focus on sustainable operations rather than short-term margin expansion.
For FY27, DLPL guides revenue growth of 13–15%, with margins expected to remain stable around 27–28%. The company plans to expand its network and infrastructure, aiming to drive long-term growth while maintaining operational discipline.
Company Overview & Others
Dr. Lal PathLabs Ltd is one of India’s leading diagnostic and healthcare testing companies, established in 1949 by Dr. S. K. Lal. The company provides a wide range of pathology and diagnostic services, including blood tests, clinical chemistry, microbiology, and molecular diagnostics. With a strong network of many laboratories and more patient service centers across India, it has become a trusted name in medical diagnostics for both routine and specialized testing.
The company focuses on quality, reliability, and innovation, leveraging advanced technology and automation in its operations. It serves hospitals, doctors, and individual patients, contributing to early diagnosis and effective treatment. Dr. Lal PathLabs has also expanded its presence internationally and continues to grow by adopting digital solutions and home collection services, making healthcare more accessible and convenient.
Dr. Lal PathLabs demonstrates strong financial health, with a Return on Capital Employed (ROCE) of 28.3% and a Return on Equity (ROE) of 22.5%, indicating efficient use of capital and consistent profitability for shareholders. The company maintains a low debt-to-equity ratio of 0.08, reflecting minimal reliance on debt and a solid, conservative financial structure.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
